Inflation, drug pricing and reimbursement constraints will have the biggest negative impact on biopharma industry in 2023: GlobalData Read more
Pricing pressures and regulatory overhang affect margins of Indian pharma companies in FY2023: ICRA Read more
Alembic Pharma receives USFDA’s final approval for Fesoterodine Fumarate extended-release tablets Read more
USFDA accepts AstraZeneca’s BLA for nirsevimab to prevent RSV lower respiratory tract disease Read more